呼吸道合胞病毒进入高发期 “预防针”尼塞韦单抗适合所有宝宝接种吗？

Core Viewpoint - The article discusses the rising concern over respiratory syncytial virus (RSV) infections among infants during the autumn and winter seasons, highlighting the importance of the monoclonal antibody Nirsevimab as a preventive measure against RSV [1][2]. Group 1: RSV Overview - RSV is a highly contagious respiratory virus that primarily affects children under the age of 2, especially those under 6 months old, with a high incidence of infection during the RSV season [1][3]. - Symptoms of RSV infection include runny nose, nasal congestion, cough, and fever, with severe cases potentially leading to bronchiolitis or pneumonia [1][2]. Group 2: Nirsevimab Details - Nirsevimab is currently the only approved preventive measure against RSV infection in China, providing protective effects for over 5 months [2][3]. - It is a long-acting monoclonal antibody that passively supplies antibodies to the body, helping to reduce the severity of symptoms rather than completely preventing infection [3][4]. Group 3: Target Population for Nirsevimab - The recommended recipients of Nirsevimab are newborns and infants entering their first RSV season, particularly those who are premature, have immune deficiencies, or congenital heart disease [3][4]. - Healthy infants who have already passed their first RSV season typically do not require the injection, as it may not be cost-effective for all children [3][4]. Group 4: Preventive Measures - Experts recommend physical barriers to prevent RSV, such as avoiding crowded places and reducing cross-infection, along with ensuring proper nutrition to enhance children's immune systems [4].